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Management of chronic total occlusions (CTO) in diabetics is challenging, with a 
recent trend towards early revascularization [ER: Percutaneous coronary 
intervention (PCI) and bypass grafting] instead of optimal medical therapy 
(OMT). We hypothesize that ER improves morbidity and mortality outcomes in 
diabetic patients with CTOs as compared to OMT.
AIM 
To determine the long term clinical outcomes and to compare morbidity and 
mortality between OMT and ER in diabetic patients with CTOs.
METHODS 
Potentially relevant published clinical trials were identified in Medline, Embase, 
chemical abstracts and Biosis (from start of the databases till date) and pooled 
hazard ratios (HR) computed using a random effects model, with significant P 
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value < 0.05. Primary outcome of interest was all-cause death. Secondary 
outcomes included cardiac death, prompt revascularization (ER) or repeat 
myocardial infarction (MI). Due to scarcity of data, both Randomized control 
trials and observational studies were included. 4 eligible articles, containing 2248 
patients were identified (1252 in OMT and 1196 in ER). Mean follow-up was 45-60 
mo.
RESULTS 
OMT was associated with a higher all-cause mortality [HR: 1.70, 95% confidence 
interval (CI): 0.80-3.26, P = 0.11] and cardiac mortality (HR: 1.68, 95%CI: 0.96-2.96, 
P = 0.07). Results were close to significance. The risk of repeat MI was almost the 
same in both groups (HR: 0.97, 95%CI: 0.61-1.54, P = 0.90). Similarly, patients 
assigned to OMT had a higher risk of repeat revascularization (HR: 1.62, 95%CI: 
1.36-1.94, P < 0.00001). Sub-group analysis of OMT vs PCI demonstrated higher 
all-cause (HR: 1.98, 95%CI: 1.36-2.87, P = 0.0003) and cardiac mortality (HR: 1.87, 
95%CI: 0.96-3.62, P = 0.06) in the OMT group. The risk of repeat MI was low in the 
OMT group vs PCI (HR: 0.53, 95%CI: 0.31-0.91, P = 0.02). Data on repeat 
revascularization revealed no difference between the two (HR: 1.00, 95%CI: 0.52-
1.93, P = 1.00).
CONCLUSION 
In diabetic patients with CTO, there was a trend for improved outcomes with ER 
regarding all-cause and cardiac death as compared to OMT. These findings were 
reinforced with statistical significance on subgroup analysis of OMT vs PCI.
Key Words: Coronary angiography; Diabetes mellitus; Percutaneous coronary Intervention; 
Coronary bypass grafts; Chronic total occlusions; Mortality
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: There is a well-known association with worse outcomes from chronic total 
occlusions in diabetics. These lesions have been traditionally treated with optimal 
medical therapy (OMT) with the standard of care for revascularization being coronary 
artery bypass grafting with little evidence of superiority over OMT. Our results reveal 
for the first time a trend towards superiority of the prompt revascularization group to 
OMT in terms of all cause and cardiac death in diabetics with chronic total occlusions. 
These findings were reinforced on subgroup analysis. However, patients undergoing 
percutaneous coronary intervention had a higher risk of repeat fatal and non-fatal 
myocardial infarction as compared to OMT. The risk for repeat revascularization was 
similar in both groups.
Citation: Khan MS, Sami FA, Singh H, Ullah W, Al-Dabbas M, Changal KH, Mir T, Ali Z, 
Kabour A. Medical therapy vs early revascularization in diabetics with chronic total occlusions: 




Chronic total occlusion (CTO) of a coronary artery is defined as a 100% stenosis with 
thrombolysis in myocardial infarction 0/I flow for greater than 3 mo[1,2]. The 
prevalence of CTOs ranges from 18%-26% in all patients with coronary artery disease 
(CAD) and almost 50% in patients with previous coronary artery bypass grafting 
(CABG)[3]. Around 10% of patients with acute myocardial infarction (MI) are also 
found to have CTOs[3]. Presence of CTO is associated with lifestyle impairment, 
reduced cardiac performance and poor long-term outcomes[3,4]. Given the complex 
nature and uncertainty regarding mortality benefit from revascularization, these 
lesions were traditionally treated with optimal medical therapy (OMT). However, with 
recent advancement in percutaneous techniques and greater operator experience along 
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with better patient selection, there has been an increase in the trend of CTO 
interventions in contemporary practice.
In this complex subset of CAD population, diabetic patients are particularly at 
higher risk of poor outcomes as compared to their non-diabetic counter-parts[5-7]. 
Despite lack of sufficient studies, recent evidence suggest that successful CTO 
revascularization is associated with improved outcomes of quality of life, left 
ventricular systolic function and potentially survival in general population[8,9]. 
However, limited data exists regarding long-term outcomes in diabetic patients with 
CTO treated with revascularization. We, therefore, conducted this meta-analysis of 
randomized clinical and observational studies to compare clinical outcomes with 
revascularization vs optimal medical therapy in diabetic patients with CTO.
MATERIALS AND METHODS
We followed the preferred reporting items for systematic reviews and meta-analyses 
guidelines, a checklist of which is available as supplementary material[10].
Search strategy
A predefined inclusion criterion was established in advance. Potentially relevant 
published clinical trials were identified in Medline, Embase, chemical abstracts and 
Biosis (from start of the databases till date). The following search items were used to 
search titles and abstracts: (Optimal medical therapy? or OMT? Or intensive medical 
therapy or IMT or revascularization? Or prompt revascularization or early 
revascularization? And diabetic or type 2 diabetes or DM and chronic total occlusion 
or CTO and clinical trials. Due to scarcity of data, both observational and 
interventional studies were included. Studies were limited to involving humans only.
Selection criteria
Two researchers independently performed an electronic search of pub med and web of 
science databases. No language restrictions were made. Studies were included if they 
met the following criteria; intervention with OMT and early revascularization (PCI or 
CABG) in diabetics as variables and primary outcome of interest as all cause death. 
Secondary outcomes included cardiac death, prompt revascularization (ER) or repeat 
MI. Studies were included if successful revascularization (CABG or PCI) was 
performed within six weeks of randomization or start of study. Both short and long 
term follow ups were included in literature review. 48 articles were identified after the 
search. The second selection step involved proof-reading of those articles to ensure the 
first step was performed correctly. Articles were excluded if data on OMT or prompt 
revascularization (ER) was missing, trials did not include diabetic subjects or primary 
and secondary outcomes of interest were not available. In case of un-clarity, inclusion 
of the studies was discussed amongst the authors to arrive at a final decision.
Data extraction and statistical analysis
Data was extracted from each study using a standardized spread sheet which involved 
study identification (Author, year of publication and country), study type, percent 
males, subject baseline characteristics with history of coronary artery disease, number 
of cases in OMT and ER arms, time of follow up, type of stent used (Drug eluting vs 
bare-metal), exclusion criteria and quality scoring.
To calculate the overall effect outcome, generic inverse variance tool under the 
random effects model to calculate pooled hazard ratios (HR) was performed using 
Cochrane's review manager. The “test for overall effect” was reported as z value 
corroborating inference from the 95% confidence interval (CI), and the probability 
value of P < 0.05 was considered statistically significant. Higgins I-squared (I2) statistic 
model was used to assess variations in outcomes of included studies. I2 values of 50% 
or less corresponded to low to moderate, and 75% or higher indicated large amounts 
of heterogeneity. Publication bias was illustrated graphically using a funnel plot 
asymmetry. The methodological quality of included articles was performed using the 
Cochrane guidelines for systematic review and meta-analysis.
We also assessed quality using a scoring system based on the Delphi consensus for 
meta-analysis[11]. The following criteria were used for scoring: Proper randomization 
(Score: 1 point), similarity of treatment groups in relevant variables at baseline (1 
point), blinding of subjects and investigators (1 point for each), specified eligibility 
criteria (1 point), valid point estimates and measures of variability (1 point) and data 
on degree of compliance (1 point). Thus, a combined score was calculated for each 
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study which could range from 0 to 7 points. For the observational studies, a score of 0 
was given for randomization. Quality scores for each study have been illustrated in 
Table 1.
RESULTS
The search through Pub med and Med of science databases yielded 48 potentially 
relevant articles. Based on predefined exclusion criteria, 44 papers were excluded for 
various reasons. 1 Randomized control trial[12] and 3 observational studies[13-15]
 involving a total of 2448 subjects were included in the meta-analysis. The number of 
subjects ranged from 236 in Yan et al[15] to 972 in Damluji et al[12]. Mean age ranged from 
59.2 years in Yan et al[15] to 68.5 years in Flores-Umanzor et al[13] Reported compliance 
was 100%. Follow up time ranged from 45 mo in Yan et al[15] To 60 mo in Damluji et al[12] 
as above, studies were included if successful revascularization (CABG or PCI) was 
performed within six weeks of randomization or start of study. OMT included 
pharmacological therapy as well as lifestyle modification. Pharmacologic therapy 
across the studies included antiplatelet therapy (as needed), maximum tolerated dose 
of anti-anginals (B-Blocker plus a long acting nitrate and/or a calcium channel 
blocker) and statins. Baseline characteristics of all studies have been illustrated in 
Table 1, with the major co-morbidities across all studies in Table 2. Among studies 
with reported data, right coronary artery was the vessel most commonly diseased 
(Table 3).
Primary effect outcome
Three out of four studies reported long term all-cause mortality. There was a 70% 
increase in risk of pooled all-cause mortality in the OMT group, although the 
confidence interval did cross 1, (HR: 1.70, 95%CI: 0.80-3.26, P = 0.11, see Figure 1A).
 Significant heterogeneity was observed, (I2= 88%, P = 0.0003). After removing the 
study by Flores-Umanzor et al[13], no significant heterogeneity was seen, (I2= 28%, P = 
0.24) however, pooled results were similar, (HR: 1.21, 95%CI: 0.79-4.19, P = 0.38, 
Figure 1B). In order to assess for publication bias, a funnel plot for each study was 
constructed against their respective precisions. Absence of publication bias is reflected 
in an intercept close to zero with the slope of regression line close to overall effect size. 
Although the small number of studies limited its interpretation however, a subjective 
impression of funnel plot demonstrated no publication bias.
Secondary effect outcomes
All four studies reported long term cardiac mortality. The long-term HR for cardiac 
mortality was 1.68 with 95%CI: 0.96-2.96 and P = 0.07 in the OMT group with an 
overall 68% increased risk as compared to the ER group, results were close to 
significance (Figure 1C). Significant heterogeneity was again observed, (I2= 76%, P = 
0.006). After removing Flores-Umanzor et al[13] from the analysis, mortality was higher 
in the OMT group, however the CI crossed 1, (HR: 1.24, 95%CI: 0.85-1.81, P = 0.27).
Data for repeat MI was available for all four studies. No significant differences in 
the hazard ratio were observed between the two groups. (HR: 0.97, 95%CI: 0.61-1.54, P 
= 0.90, Figure 2A). No significant heterogeneity was observed, (I2= 41%, P = 0.16).
All four studies reported data on repeat revascularization (PCI and CABG). There 
was a 62% increase in risk of repeat revascularization in patients assigned to medical 
therapy, and results were statistically significant, (HR: 1.62, 95%CI: 1.36-1.94, P < 
0.00001, Figure 2B). No publication bias or study heterogeneity was observed, I2= 0%.
Subgroup analysis
Sub-group analysis stratified by mode of revascularization i.e. CABG or PCI was also 
performed for both primary and secondary effect outcomes. Only Flores-Umanzor 
et al[13] provided data on both PCI and CABG where as two studies provided data on 
PCI only. Thus, subgroup analysis was done only for PCI.
For all-cause mortality, sub group analysis of OMT vs PCI revealed a 98% increased 
risk in the OMT group, (HR: 1.98, 95%CI: 1.36-2.87, P = 0.0003, Figure 3A). This was 
statistically significant with no significant heterogeneity, (I2= 0, P = 0.83).
Similarly, sub-group analysis for cardiac mortality was also done comparing PCI vs 
OMT. Three out of four studies i.e., Flores-Umanzor et al[13] and Yan et al[15] provided 
data on PCI. There was an 87% increased risk of cardiac mortality in the OMT vs PCI 
group, (HR: 1.87, 95%CI: 0.96-3.62, P = 0.06, Figure 3B). Results were not statistically 
significant with moderate heterogeneity, (I2= 60%, P = 0.08).
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Table 1 Baseline characteristics of all studies




Yan et al[15] Choi et al[14]
Type of 
study




Cohort (retrospective) Cohort (retrospective)










972 538 2361 702
Follow up in 
months
60 48 45 46
Male (%) 78 82 78 77
Age, mean 
(yr)
62.5 68.5+/-3.5 60 64.6
Type of stent 
used if PCI
DES or BMS - DES DES
Exclusion 
criteria
Need for immediate revascularization, 
left main coronary disease, a creatinine 
level > 2.0 mg/dL, a glycated 
hemoglobin level > 13.0%, heart failure 
class III or IV, hepatic dysfunction, or 




(1) Patients who had a history of CABG; (2) 
Patients who had acute myocardial infarction 
(MI) due to non-CTO vessels 1 mo before the 
study; (3) Patients who had left main 
coronary artery disease; and (4) Patients who 
had histories of cancer or other diseases that 
could confuse the end points
History of previous CABG; 
history of cardiogenic shock or 
cardiopulmonary resuscitation; 
ST-segment elevation acute MI 
during the preceding 48 h
Quality 
score2
7 5 5 5
1Propensity Matched Population.
2Criteria used for scoring: Proper Randomization (Score: 1 point), similarity of treatment groups in relevant variables at baseline (1 point), blinding of 
subjects and investigators (1 point for each), specified eligibility criteria (1 point), valid point estimates and measures of variability (1 point) and data on 
degree of compliance (1 point). More details in text. DM: Diabetes mellitus; CTO: Chronic total occlusion; PCI: Percutaneous coronary intervention; RCT: 
Randomized control trial; DES: Drug eluting stent; BMS: Bare metal stent; CABG: Coronary artery bypass grafting.
Three out of four studies i.e. Flores-Umanzor et al[13], Choi et al[14] and Yan et al[15] 
provided data on risk of repeat MI. OMT was relatively safer in regards to occurrence 
of repeat MI as compared with PCI with a decreased HR, (HR: 0.53, 95%CI: 0.31-0.91, P 
= 0.02, Figure 3C). No heterogeneity was observed, I2= 0%, P = 0.87.
For repeat revascularization, sub group analysis of OMT vs PCI revealed no 
difference in HR between the two groups. (HR: 1.00, 95%CI: 0.52-1.93, P = 1.00, 
Figure 3D).
DISCUSSION
In this meta-analysis of randomized controlled and observational studies comparing 
diabetic patients with CTOs, patients in the OMT group were found to have a higher 
risk of all-cause and cardiac death as compared to ER. We included 4 studies for a total 
of 2448 patients. 1252 patients were treated with OMT while 1196 patients underwent 
early revascularization. Damluji et al[12] which is a post hoc analysis of the bypass 
angioplasty revascularization investigation 2 diabetes trial, evaluated the influence of 
CTO on long term clinical outcomes of patients with coronary artery disease and 
diabetes mellitus. We extracted the data for CTO only from Damluji et al[12] to calculate 
mortality and morbidity outcomes in diabetics, however, our results were non-
significant as shown in Figures 1A-1C further 3 observational studies were added to 
our meta-analysis to achieve the above results. We found that there was a trend of 
improved survival with ER either with CABG or PCI in terms of cardiac and all cause 
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OMT (n = 490) ER (n = 
482)
OMT (n = 326) ER ER OMT (n = 
118)
ER (n = 
118)
OMT (n = 
318)
ER (n = 
384)
PCI (n = 76) CABG (n = 
136)
HTN 80 (385) 81 (387) 85 (276) 82 ( 62) 86 (117) 66.9 (79) 71.2 (84) 70.7 (225) 70.3 (270)
Previous MI 44 (214) 41 (197) 33 (108) 28 (21) 28 (21) 56.8 (67) 55.9 (66) 34.9 (111) 18.0 (69)
Prior CHF 7 (36) 9 (43) - - - 14.4 (17) 10.2 (12) - -
Prior Stent/PCI 11 (56) 12 (59) - - - 48.3 (57) 42.4 (50) 30.5 (97) 22.1 (85)
Prior CVA/TIA 10 (49) 10 (46) - - - 5.1 (6) 5.9 (7) 12.3 (39) 11.2 (43)
Prior Revascularizatio 31 (151) 26 (124) - - - - - - -
Prevnious CABG - - 14 (45) 5 (4) 4 (5) - - 0 0
HbA1c mean 7.4 7.3 7.6 ± 0.1 7.6 ± 0.2 7.3 ± 0.1 - - - -
Dyslipidemia 83 (402) 84 (400) 75 (246) 71 (54) 74 (100) 51.7 (61) 50 (59) 21.7 (69) 31.3 (120)
Smoking - - 52 (169) 55 (42) 59 (80) 55.9 (66) 57.6 (68) 28.6 (91) 32.8 (126)
Peripheral vascular 
disease
- - 45 (145) 33 (25) 35 (47) 3.4 (4) 3.4 (4) 6.0 (19) 3.4 (13)
1Data given separately for percutaneous coronary intervention and Coronary Artery Bypass Grafting group. OMT: Optimal medical therapy; ER: Early 
revascularization; N: Number of subjects; PCI: Percutaneous coronary intervention; CABG: Coronary Artery Bypass Grafting; HTN: Hypertension; MI: 
Myocardial infarction; CHF: Heart failure; CVA: Cerebrovascular accident, HbA1c: Hemoglobin A1c.
Table 3 Chronic total occlusions location with number of chronic total occlusions lesions among studies in percentages (actual 
prevalence in brackets)
Ref. Damluji et al[12]
Flores-Umanzor 
et al[13] Yan et al
[15] Choi et al[14]
OMT ER OMT (n = 326) ER (n = 212) OMT (n = 
118)
ER (n = 
118)
OMT (n = 
318)
ER (n = 384)
Number of CTO lesions
1 - - 80 (261) 75 (159) - -
2 - - 79 (60) 24 (50) - -
3 - - 1.5 (5) 1.4 (3) - -
CTO location
LAD artery - - 18 (60) 24 (51) 30.5 (36) 28.0 (33) 26.4 (84) 38.5 (148)
LCX artery - - 19 (62) 20 (42) 28.0 (33) 26.3 (31) 36.5 (116) 29.2 (112)
RCA - - 52 (170) 47 (100) 41.5 (49) 45.8 (54) 56.3 (117) 47.9 (184)
Other coronary artery 
branches
- - 10 (34) 9 (19) - - - -
LAD: Left anterior descending; LCX: Left circumflex; RCA: Right coronary artery; OMT: Optimal medical therapy; ER: Early revascularization; N: number 
of subjects.
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death. To our knowledge, this is the first ever meta-analysis of clinical trials comparing 
morbidity and mortality outcomes in diabetic patients with a CTO. Our subgroup 
analysis also revealed poor performance of PCIs vs OMT in terms of incidence of 
combined fatal and non-fatal MI. Further stratification could not be performed due to 
paucity of data.
Given the complex nature and uncertainty regarding mortality or morbidity benefits 
from percutaneous or surgical revascularization, CTO lesions have been traditionally 
treated with OMT. Historically, the standard of care for revascularization of CTO 
lesions has been CABG with little evidence of superiority over OMT. However, with 
recent advancement in percutaneous techniques and greater operator experience along 
with better patient selection, there has been an increase in trend of CTO interventions 
in contemporary practice[16,17]. Although observational data has shown a reduction in 
Major Adverse Cardiac Events, global left ventricular ejection fraction and quality of 
life after revascularization of CTO, results from these trials are inconsistent[18,19].
 Currently the global expert consensus statement recommends PCI revascularization 
for ischemic symptom improvement for which data is more unanimous[20].
Diabetes mellitus is a major risk factor of CTO. Around 34%-40% of patients with 
CTO have a history of diabetes[13] and there is a well-known association with worse 
outcomes from CTO in diabetics[5-7,13]. Diabetes leads to endothelial cell dysfunction 
and changes in microcirculation, a prothrombotic/proinflammatory state along with 
impaired formation of coronary collaterals[7,8,21]. This causes aggressive progression of 
atherosclerosis within the arterial bed including the coronary arteries leading to poorer 
outcomes in patients with CAD[22]. PCI in diabetic patients also has a higher risk of in-
stent restenosis, repeat revascularization, MI, stent thrombosis and death when 
compared to non-diabetics[23-25].
By performing a post hoc analysis of the bypass angioplasty revascularization 
investigation 2 diabetes trial, Damluji et al[12] was the first to compare clinical outcomes 
in patients with both diabetes and coronary artery disease. They found that a lot of 
diabetic patients with CAD had a high prevalence of CTOs, approximately 41%. 
Although the primary outcome studied was the effect of CTOs on mortality in 
diabetics with a strongly positive correlation, we extracted the data for the CTO 
subgroup only for our analysis and found that OMT was associated with a higher risk 
of all cause and cardiac mortality in diabetics. Patients undergoing early 
revascularization were also noted to have a lower risk of repeat MI and repeat 
revascularization at long term follow up. Damluji et al[12] and Choi et al[14] however did 
not perform a subgroup analysis on the revascularization modality chosen i.e., CABG 
vs PCI.
Our subgroup analysis (OMT vs PCI) revealed inferiority of PCI as a 
revascularization strategy in terms of repeat MI and repeat revascularization to the 
combined PCI and CABG group. This discrepancy in results is an interesting 
observation from the PCI subset as compared to the combined revascularization 
pool. This could imply superiority of CABG over PCI in these patients but these results 
might be confounded by disease anatomy and various comorbidities. Studies designed 
to compare CABG and PCI for this purpose can be helpful in the future. Also, the 
current success rates of CTO-PCI in the general population are from 80%-85%, 
however the majority of our trials demonstrated a lower success rate[26]. One possible 
explanation for this discrepancy could be recent advancements in percutaneous 
techniques and equipment, however it is well known that diabetic patients have a 
higher burden of CAD with more complex disease anatomy which might be difficult 
to completely re-vascularize[27]. In a meta-analysis of 35 studies including 89883 
patients, Garcia et al[28] demonstrated that CABG was twice as likely as PCI to achieve 
complete revascularization in patients with CTOs. The study by Flores-Umanzor 
et al[13] included in our meta-analysis also noted higher rates of anatomic and 
functional complete revascularization in CABG vs PCI patients (63% and 62% vs 36% 
and 32%, P < 0.01). Subsequently, they also reported statistically significant lower all-
cause and cardiac mortality with CABG when compared to MT group but not with 
PCI.
Another important factor to consider in these patients is the presence or absence of 
chronic kidney disease (CKD). Studies have shown that renal dysfunction is an 
independent risk factor for cardiovascular disease, with higher mortality rates for both 
myocardial infarction and sudden cardiac death[29,30]. Our patients in Choi et al[14] and 
Yan et al[15] were case-control matched according to the presence or absence of CKD, 
however, further data on this sub-group was not available for us to perform analysis. 
Similarly, the study referenced by Damluji et al[12] excluded patients with a creatinine 
of 2.0 mg/dL or higher. Flores-Umanzor et al[13] did not comment on CKD. Hopefully, 
further studies in the future shall enable us to look at the effect of CKD on clinical 
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Figure 1 Random effects meta-analysis and forest plot of hazard ratios for all cause long term and cardiac mortality. A: All-cause Mortality; B: 
All-cause mortality after removing Flores-Umanzor et al[13]; and C: Cardiac Mortality.
Figure 2 Random effects meta-analysis and forest plot of hazard ratios for repeat myocardial infarction and repeat revascularization. A: 
Repeat Myocardial Infarction; and B: Repeat revascularization.
outcomes in diabetics with CTO.
It is also not clear why revascularization in CTO is beneficial and associated with 
improved survival rates in diabetics. CTOs are usually associated with a larger scar 
and most of all with a bigger border zone which causes arrhythmias and sudden 
cardiac death in most patients[31]. Thus, it might be the beneficial effects of early 
revascularization in preventing the formation of scar myocardium which may lead to 
improvement in mortality and morbidity. It also might be worthwhile to attempt 
CABG instead of PCI in patients with a difficult anatomy particularly in the diabetic 
sub group as these patients have a lower success rate as compared to the general 
population and might save unnecessary side effects from an unsuccessful procedure in 
itself.
Limitations
Our studies have various limitations. Because of the observational design of three out 
of four studies (Figures 1 and 2), there was an inherent risk of selection bias which 
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Figure 3 Sub-group analysis and forest plot of hazard ratios for all-cause and cardiac mortality, repeat mi and repeat revascularization. A: 
All-Cause Mortality; B: Cardiac mortality; C: Repeat myocardial infarction; and D: Repeat revascularization.
may have affected the results through confounding factors. One of the potential 
explanations for the mortality benefits with ER may be potential confounders as high-
risk patients are less likely to undergo ER. This was reinstated across all studies as 
patients assigned to OMT were older and with more co-morbidities. A major concern 
for selection bias in Flores-Umanzor et al[13] was the inclusion of failed PCI group into 
the medical therapy group as a failed PCI might itself be a risk factor for adverse 
events in the future. Yan and colleagues also only studied one vessel CTO but the 
other three studies also included more than one vessel CTO. Although this might not 
be significant as Flores-Umanzor et al[13] demonstrated that in majority of patients, only 
one vessel was diseased with the most common culprit being the right coronary artery. 
The selection of only PCI as revascularization modality by Choi et al[14] and Yan et al[15] 
also introduced bias as patients treated with CABG were not studied. Significant 
heterogeneity was observed in some effect outcomes, however we used sensitivity 
analysis to analyze which study was causing the effect and recalculated data after 
dropping the study. Also, as with all met-analysis, the quality of the study is as good 
as the quality of the trials itself.
CONCLUSION
Despite our limitations, we report the results of the first meta-analysis specifically 
done on diabetic patients with CTO lesions treated with OMT vs ER. The results reveal 
a trend towards superiority of the ER group (PCI and CABG) to OMT in terms of all 
cause and cardiac death although we could not achieve statistical significance. These 
findings were reinforced on subgroup analysis of OMT vs PCI, specifically regards to 
all-cause death where the results were statistically significant. However, patients 
undergoing PCI had a higher risk of repeat fatal and non-fatal MI as compared to 
OMT and the risk for repeat revascularization was similar in both groups. 
Overall patients in the OMT only group had a higher risk of repeat revascularization 
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as compared to ER group (PCI and CABG). In patients with extensive CAD and CTO, 
CABG may be attempted as PCI in diabetics has a higher risk of failure as compared to 
non-diabetics. Further data including larger patient population from future studies is 




The thought process behind this manuscript was our motivation upon literature 
review of a scarcity of data involving clinical outcomes of diabetics with chronic total 
occlusion (CTO) of coronary vessels.
Research motivation
Our motivation came from the scarcity of data in this sub group of population. There 
exists a lot of literature comparing the mortality and morbidity outcomes of medical 
therapy (OMT) vs early re-vascularization [ER: Percutaneous coronary intervention 
(PCI) + Coronary artery bypass grafting] in patients with chronic total occlusions but 
none in the diabetic subset.
Research objectives
To compare the mortality and morbidity outcomes in diabetic population with CTO 
treated with OMT vs ER.
Research methods
Multiple electronic data-bases including Pubmed, Embase were searched involving 
human studies comparing OMT vs ER in patients having CTO of coronary vessels. 
Data was analyzed using Cochrane review manager with hazard ratios using the 
random effects model. Primary effect estimate was all cause mortality with secondary 
effect estimates as cardiac mortality, repeat myocardial infarction (MI) and repeat re-
vascularization.
Research results
Statistical analysis revealed a higher risk for all-cause mortality, cardiac mortality and 
repeat re-vascularization in the OMT group. For repeat MI, data analysis revealed no 
significant differences in between the two groups. Sub-group analysis was also done 
for OMT vs PCI. This revealed a higher risk for all-cause mortality but not for 
cardiac mortality or repeat re-vascularization in the OMT group. Interestingly, patients 
in the OMT group were found to have a lower incidence of repeat MI vs PCI group.
Research conclusions
There is a trend towards superiority of the ER group as compared to OMT group in 
diabetic patients with a CTO. These findings were reinforced on sub-group analysis of 
OMT vs PCI.
Research perspectives
Despite our limitations, we present the first ever meta-analysis specifically involving 
diabetic patients only with CTO treated with OMT or ER. Although we were able to 
demonstrate a trend towards superiority of the ER group, this was not statistically 
significant for some sub-groups including all-cause and cardiac mortality. Although 
this manuscript provides a relatively new insight into management of such patients, 
further studies may be needed before a consensus is developed.
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